207_Combined course Presentations

CATNON trial : New standard regimen for non-codeleted anaplastic glioma ?

100

Overall Survival

90

RT + adjuvant TMZ

80



748 patients randomized

RT alone

70

60



12 cycles TMZ improve OS in anaplastic glioma without 1p/19q codeletion.

50

40

 MGMT methylation was prognostic for OS, but did not predict improved outcome to adjuvant TMZ

30

p < 0.001

20

10

0

years

0

1

3

7

8

4

5

2

6

Van den Bent MJ. et al. presented at ASCO 2016 annual meeting, Chicago